HUTCHMED (China) Analyst Price Targets

HUTCHMED (China) Ltd

HCMNASDAQ

Trade with Public

$14.18

0.130.93%

Dern. MÀJ: Oct 20, 6:15 AM

$14.65

0.604.27%

Aperçu Actualités Prévisions de résultats ÉvénementsObjectifs de coursDonnées financières Sentiment Comparer Options Rapport sur les stocks

HUTCHMED (China) Analyst Price Targets

Wall Street analyst price targets and consensus rating for HUTCHMED (China) (HCM).

Price Target Range — 5 Quarters

Analyst Consensus — 4 Analysts

2Buy

1Hold

1Sell

Consensus RatingBuy# Analysts4Avg. Consensus PT$17Upside to Avg. PT+18.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →

Date	Firm	Analyst	Action	Rating Change	Price Target
Jul 23, 2026	Goldman Sachs	Paul Choi	PT Cut	Neutral	$16→$14
Jul 7, 2026	B of A Securities	Alec Stranahan	PT Cut	Buy	$20→$17
Mar 10, 2026	B of A Securities	Dimple Gosai	PT Cut	Buy	$21→$20
Sep 22, 2025	Morgan Stanley	Jack Lin	Downgrade	Equal-Weight→Underweight	$18→$14
Jul 22, 2025	B of A Securities	Dimple Gosai	PT Raise	Buy	$27→$28
Aug 1, 2024	Goldman Sachs	Paul Choi	PT Raise	Neutral	$17→$19
Nov 24, 2023	Deutsche Bank	Cyrus Ng	Upgrade	Hold→Buy	$20→$22
Nov 10, 2023	Goldman Sachs	Paul Choi	PT Raise	Neutral	$15→$17

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Goldman Sachs Maintains Neutral on HUTCHMED (China), Lowers Price Target to $14

Goldman Sachs analyst Paul Choi maintains HUTCHMED (China) (NASDAQ:HCM) with a Neutral and lowers the price target from $16 to $14.

Benzinga Newsdesk

PRO
B of A Securities Maintains Buy on HUTCHMED (China), Lowers Price Target to $17

B of A Securities analyst Alec Stranahan maintains HUTCHMED (China) (NASDAQ:HCM) with a Buy and lowers the price target from $20 to $17.

Benzinga Newsdesk

PRO
B of A Securities Maintains Buy on HUTCHMED (China), Lowers Price Target to $20

B of A Securities analyst Dimple Gosai maintains HUTCHMED (China) (NASDAQ:HCM) with a Buy and lowers the price target from $21 to $20.

Benzinga Newsdesk

PRO
Morgan Stanley Downgrades HUTCHMED (China) to Underweight, Lowers Price Target to $13.75

Morgan Stanley analyst Jack Lin downgrades HUTCHMED (China) (NASDAQ:HCM) from Equal-Weight to Underweight and lowers the price target from $18 to $13.75.

Benzinga Newsdesk

PRO
B of A Securities Maintains Buy on HUTCHMED (China), Raises Price Target to $28

B of A Securities analyst Dimple Gosai maintains HUTCHMED (China) (NASDAQ:HCM) with a Buy and raises the price target from $27 to $28.

Benzinga Newsdesk

PRO
Goldman Sachs Maintains Neutral on HUTCHMED (China), Raises Price Target to $19

Goldman Sachs analyst Paul Choi maintains HUTCHMED (China) (NASDAQ:HCM) with a Neutral and raises the price target from $17 to $19.

Benzinga Newsdesk

HUTCHMED (China) Ltd

HUTCHMED (China) Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Goldman Sachs Maintains Neutral on HUTCHMED (China), Lowers Price Target to $14

PRO
B of A Securities Maintains Buy on HUTCHMED (China), Lowers Price Target to $17

PRO
B of A Securities Maintains Buy on HUTCHMED (China), Lowers Price Target to $20

PRO
Morgan Stanley Downgrades HUTCHMED (China) to Underweight, Lowers Price Target to $13.75

PRO
B of A Securities Maintains Buy on HUTCHMED (China), Raises Price Target to $28

PRO
Goldman Sachs Maintains Neutral on HUTCHMED (China), Raises Price Target to $19

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

HUTCHMED (China) Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Goldman Sachs Maintains Neutral on HUTCHMED (China), Lowers Price Target to $14

PRO
B of A Securities Maintains Buy on HUTCHMED (China), Lowers Price Target to $17

PRO
B of A Securities Maintains Buy on HUTCHMED (China), Lowers Price Target to $20

PRO
Morgan Stanley Downgrades HUTCHMED (China) to Underweight, Lowers Price Target to $13.75

PRO
B of A Securities Maintains Buy on HUTCHMED (China), Raises Price Target to $28

PRO
Goldman Sachs Maintains Neutral on HUTCHMED (China), Raises Price Target to $19

People Also Watch

People Also Watch

HUTCHMED (China) Ltd

HUTCHMED (China) Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROGoldman Sachs Maintains Neutral on HUTCHMED (China), Lowers Price Target to $14

PROB of A Securities Maintains Buy on HUTCHMED (China), Lowers Price Target to $17

PROB of A Securities Maintains Buy on HUTCHMED (China), Lowers Price Target to $20

PROMorgan Stanley Downgrades HUTCHMED (China) to Underweight, Lowers Price Target to $13.75

PROB of A Securities Maintains Buy on HUTCHMED (China), Raises Price Target to $28

PROGoldman Sachs Maintains Neutral on HUTCHMED (China), Raises Price Target to $19

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

HUTCHMED (China) Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROGoldman Sachs Maintains Neutral on HUTCHMED (China), Lowers Price Target to $14

PROB of A Securities Maintains Buy on HUTCHMED (China), Lowers Price Target to $17

PROB of A Securities Maintains Buy on HUTCHMED (China), Lowers Price Target to $20

PROMorgan Stanley Downgrades HUTCHMED (China) to Underweight, Lowers Price Target to $13.75

PROB of A Securities Maintains Buy on HUTCHMED (China), Raises Price Target to $28

PROGoldman Sachs Maintains Neutral on HUTCHMED (China), Raises Price Target to $19

People Also Watch

People Also Watch

PRO
Goldman Sachs Maintains Neutral on HUTCHMED (China), Lowers Price Target to $14

PRO
B of A Securities Maintains Buy on HUTCHMED (China), Lowers Price Target to $17

PRO
B of A Securities Maintains Buy on HUTCHMED (China), Lowers Price Target to $20

PRO
Morgan Stanley Downgrades HUTCHMED (China) to Underweight, Lowers Price Target to $13.75

PRO
B of A Securities Maintains Buy on HUTCHMED (China), Raises Price Target to $28

PRO
Goldman Sachs Maintains Neutral on HUTCHMED (China), Raises Price Target to $19

PRO
Goldman Sachs Maintains Neutral on HUTCHMED (China), Lowers Price Target to $14

PRO
B of A Securities Maintains Buy on HUTCHMED (China), Lowers Price Target to $17

PRO
B of A Securities Maintains Buy on HUTCHMED (China), Lowers Price Target to $20

PRO
Morgan Stanley Downgrades HUTCHMED (China) to Underweight, Lowers Price Target to $13.75

PRO
B of A Securities Maintains Buy on HUTCHMED (China), Raises Price Target to $28

PRO
Goldman Sachs Maintains Neutral on HUTCHMED (China), Raises Price Target to $19